The American College of Obstetricians and Gynecologists (ACOG) has issued decisive new clinical guidance declaring there is no safe level of marijuana during pregnancy and recommending universal screening for cannabis use throughout pre-pregnancy, pregnancy, and postpartum periods.

The authoritative medical organisation’s statement directly challenges the increasingly prevalent misconception that cannabis represents a safe or beneficial option for expectant mothers, citing substantial evidence linking marijuana use to serious maternal and neonatal health risks.

Clear Medical Consensus on Pregnancy Cannabis Risks

ACOG’s new clinical consensus addresses a troubling public health trend head-on. The organisation’s statement explains: “Despite the fact that cannabis use in pregnancy has been associated with spontaneous preterm birth, low birth weight, NICU admissions, and postnatal neurocognitive and behavioural dysfunction, there is a misperception in the general public that cannabis is safe for use during pregnancy due to its increasing availability, legalisation, and social acceptability.”

The guidance represents a significant intervention by one of the most respected medical bodies in obstetrics, joining numerous other expert organisations in warning against cannabis use during this critical period.

No Therapeutic Justification for Cannabis Use

Perhaps most significantly, ACOG explicitly rejects claims that marijuana during pregnancy serves any legitimate medical purpose. The organisation states unequivocally: “There is no medical indication for cannabis use during pregnancy and the postpartum period.”

This position directly contradicts marketing narratives suggesting cannabis can safely address conditions including anxiety, depression, insomnia, and chronic pain, as well as pregnancy-related symptoms such as nausea and vomiting. The medical consensus from this non-partisan, highly credentialed field could not be clearer: pregnant cannabis use offers no therapeutic benefit whilst carrying substantial risks.

Growing Evidence of Harm to Maternal and Foetal Health

The recommendation for universal screening reflects mounting scientific evidence about cannabis-related pregnancy risks. Recent research has documented how marijuana during pregnancy correlates with multiple adverse outcomes affecting both mothers and babies.

A groundbreaking study from Canadian and Israeli researchers revealed that THC exposure drives a significant increase in embryos developing with abnormal chromosome numbers. The research also demonstrated that cannabis can disrupt the genetic transcription process, raising serious concerns about foetal development at the most fundamental cellular level.

These fertility-related findings compound an already extensive list of documented harms. Cannabis use has been linked to severe cardiac complications, connections to serious mental illness, and endocrine system damage—all particularly concerning for pregnant individuals whose bodies undergo profound physiological changes.

Public Misperceptions Fuel Dangerous Trends

ACOG’s intervention comes at a critical juncture, as concerning numbers of women report using cannabis whilst pregnant. The organisation’s emphasis on “misperception in the general public” highlights how normalisation and commercial availability have created a dangerous gap between scientific evidence and popular understanding.

The recommendation for pre-pregnancy screening acknowledges that cannabis effects on reproductive health begin before conception. Evidence suggests that pregnancy cannabis use should be discouraged well in advance of attempted conception, given the demonstrated impacts on chromosomal integrity and fertility outcomes.

Commercialisation Versus Medical Evidence

The new guidance implicitly addresses how cannabis industry expansion has outpaced public awareness of associated health risks. As legalisation spreads and commercial interests promote cannabis products, evidence-based medical guidance becomes increasingly vital to counter misleading wellness narratives.

ACOG’s position that there exists no medical indication for marijuana during pregnancy fundamentally challenges industry marketing that positions cannabis as a natural remedy for pregnancy discomforts. If cannabis fails to provide legitimate therapeutic benefit for pregnant women—whilst carrying documented risks—the logic extends to questioning its promoted benefits for other populations as well.

Screening as Prevention Strategy

Universal screening represents a proactive public health approach, enabling healthcare providers to identify cannabis use early and provide appropriate counselling and intervention. The recommendation spans pre-pregnancy, pregnancy, and postpartum periods, recognising that risks persist beyond delivery.

By calling for routine screening, ACOG signals that marijuana during pregnancy constitutes a significant enough concern to warrant systematic medical attention comparable to screening for other substance use and health risk factors.

The organisation’s statement that actual science—rather than commercial advocacy—must dominate the narrative around cannabis and public health dangers reflects growing concern within the medical community about the gap between marketing claims and clinical evidence.

Implications for Policy and Practice

ACOG’s decisive stance provides crucial support for healthcare providers navigating patient questions about cannabis use. Armed with clear guidance from their primary professional organisation, obstetricians and gynaecologists can confidently counsel patients about avoiding marijuana during pregnancy and the postpartum period.

The recommendation also carries implications for public health policy, potentially informing regulatory approaches to cannabis marketing and product labelling, particularly regarding claims about safety during pregnancy or therapeutic benefits for pregnancy-related conditions.

As cannabis accessibility and social acceptance continue expanding, ACOG’s evidence-based guidance offers an essential counterweight to commercial narratives that downplay or ignore documented health risks. The message to expectant mothers and those planning pregnancy remains unambiguous: cannabis use carries serious risks without offering any compensatory medical benefits.

Source: The Drug Report